Inhibikase Therapeutics

General Information


We are a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. We filed two Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2019 for our lead asset candidate, IkT-148009. One IND is for the treatment of Parkinson’s Disease, while the second is for treatment of gastrointestinal, or GI, complications that arise as early symptoms of PD in patients. 

Employees: 2
Founded: 2010
Contact Information
Address 3350 Riverwood Parkway SE, Suite 1927, Atlanta, Georgia, 30339, US
Phone Number (678) 392-3419
Web Address
View Prospectus: Inhibikase Therapeutics
Financial Information
Market Cap $115.7mil
Revenues $0.8 mil (last 12 months)
Net Income $-4.5 mil (last 12 months)
IPO Profile
Symbol IKT
Exchange NASDAQ
Shares (millions): 2.3
Price range $10.00 - $12.00
Est. $ Volume $25.0 mil
Manager / Joint Managers ThinkEquity​ (a division of Fordham Financial Management)
CO-Managers Paulson Investment Co.
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change